Research programme: anti-PSCA monoclonal antibodies - Agensys/Merck

Latest Information Update: 24 Aug 2011

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

24 Aug 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
08 Sep 2008 Preclinical development is ongoing in USA
17 Oct 2005 Agensys and Merck & Co have entered into an agreement to co-develop and co-promote compounds arising from this research programme worldwide for prostate cancer as well as additional cancer indications

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com